Phar 7.08(3)(b)(b) Form, dose, route of administration and duration for drug therapy. Phar 7.08(3)(d)(d) Directions and precautions for the preparation, administration, and use. Phar 7.08(3)(e)(e) Common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance, and the action required if they occur. Phar 7.08(3)(h)(h) Proper storage and appropriate disposal method of unwanted or unused medication. Phar 7.08(4)(4) The consultation required in this section shall be communicated verbally when in the pharmacist’s professional judgment it is in the best interest of the patient. Phar 7.08(5)(5) A pharmacist shall provide the patient or patient’s agent, for all consultations required under sub. (1), a written patient drug education monograph. Phar 7.08(6)(6) The consultation required in this section may occur before or after delivery of the prescription to the patient or patient’s agent. Phar 7.08(7)(7) Every licensed pharmacy dispensing directly to a patient or patient’s agent inside the pharmacy shall conspicuously post a board approved sign stating a patient’s rights to pharmacist consultation and information on how to file a complaint to the board. Phar 7.08(8)(8) A prescription drug or device delivered by common carrier, mail, or delivery service or picked up at a drive through window shall include a copy of information which is board-approved stating a patient’s rights to pharmacist consultation and information on how to file a complaint to the board. Phar 7.08 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21; correction in (3) (d) made under s. 35.17, Stats., Register December 2020 No. 780. Phar 7.085Phar 7.085 Delivery by common carrier or delivery services. Utilization of common carrier or delivery services to deliver a prescription to a location of the patient’s choice from the pharmacy which fills the prescription to the patient or patient’s agent shall ensure all of the following: Phar 7.085(1)(1) The delivery method is appropriate to prevent drug adulteration. Phar 7.085(2)(2) The patient or patient’s agent is provided a method by which the patient or patient’s agent can notify the pharmacy as to any irregularity in the delivery of the prescription drug product or device, including all of the following: Phar 7.085(2)(c)(c) Failure to receive the proper prescription drug product or device. Phar 7.085(3)(3) Any prescription drug product or device which is compromised or lost shall be replaced by the pharmacy at no additional cost to the patient. If the timeliness of the replacement will lead to an interruption in therapy, a pharmacist at the dispensing pharmacy shall take steps to mitigate patient harm. Phar 7.085 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21. Phar 7.09Phar 7.09 Procurement, recall and out-of-date drugs and devices. Phar 7.09(1)(1) A pharmacy shall have a system for identifying a drug or device subjected to a product recall and for taking appropriate actions as required by the recall notice. Phar 7.09(2)(2) A drug or device may not be dispensed after the drug’s or device’s expiration date or beyond use date. Outdated drugs or devices shall be removed from dispensing stock and shall be quarantined until such drugs or devices are properly disposed. Phar 7.09 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21. Phar 7.10Phar 7.10 Return or exchange of health items. Phar 7.10(1)(a)(a) “Health item” means drugs, devices, hypodermic syringes, needles or other objects for injecting a drug product, or items of personal hygiene. Phar 7.10(1)(b)(b) “Original container” means the container in which a health item was sold, distributed, or dispensed. Phar 7.10(1)(c)(c) “Tamper-evident package” means a package that has one or more indicators or barriers to entry which, if breached or missing, can reasonably be expected to provide visible evidence that tampering has occurred. Phar 7.10(2)(2) No health item after taken from a pharmacy where sold, distributed or dispensed, may be returned to that pharmacy, except for any of the following: Phar 7.10(2)(a)(a) Where the health item was dispensed in error, was defective, adulterated, or misbranded. Phar 7.10(2)(b)(b) When in the professional judgment of the pharmacist substantial harm could result to the public or patient if it were to remain in the possession of the patient, patient’s family or agent, or other person. Phar 7.10(2)(c)(c) A health item that is prepackaged for consumer use without a prescription when returned in compliance with all applicable state and federal laws. Phar 7.10 NoteNote: The DEA does not permit the return of controlled substances to a pharmacy from a non-DEA registrant under any circumstances.
Phar 7.10(3)(3) A health item returned to a pharmacy pursuant to sub. (2) (a) and (b), may not be sold, resold, or repackaged and sold or resold, given away, or otherwise distributed or dispensed. A returned health item shall either be destroyed at the pharmacy or delivered for destruction or other disposal by an authorized person or entity. Phar 7.10(4)(4) It is not a return of a health care item if a patient or agent of a patient delivers a previously dispensed drug or device to a pharmacy for the purpose of repackaging and relabeling of that previously dispensed drug or device, and subsequent return of the drug or device is for the same patient’s use. Phar 7.10 NoteNote: The DEA does not permit the return of controlled substances to a pharmacy from a non-DEA registrant under any circumstances.
Phar 7.10(5)(5) It is not a return of a health care item if a patient or agent of a patient delivers a previously dispensed drug or device to a pharmacy for the purpose of destruction at the pharmacy or other disposal by an authorized person or entity. Phar 7.10(6)(6) This section does not prohibit participation in a drug repository program in accordance with ch. DHS 148. Phar 7.10 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21. Phar 7.11(1)(1) General. Pharmacy records shall be maintained for a minimum period of 5 years unless otherwise specified in state or federal law. Phar 7.11(2)(a)(a) A computerized system may be used for maintaining a record, as required under this section, of prescription dispensing and transfers of prescription order information for the purposes of original or refill dispensing if the system is: Phar 7.11(2)(a)1.1. Capable of producing a printout of any prescription data which the user pharmacy is responsible for maintaining. Phar 7.11(2)(a)2.2. Equipped with an auxiliary procedure which, during periods of down-time, shall be used for documentation of prescription dispensing. The auxiliary procedure shall ensure that prescription refills are authorized by the original prescription order, that the maximum number of prescription refills has not been exceeded and that all of the appropriate data are retained for on-line entry as soon as the computer system is again available for use. Phar 7.11(2)(b)(b) A record of all prescriptions dispensed shall be maintained for a minimum period of 5 years after the date of the last refill. Phar 7.11(2)(c)(c) All systems used for maintaining a record of any prescription dispensing shall contain all items required in the medical profile record system. Phar 7.11(2)(d)(d) A paper prescription for non-controlled substances may be scanned and stored electronically in the computer system under par. (a). For purposes of this chapter, the prescription becomes an electronic prescription. Phar 7.11(3)(a)(a) An individual medication profile record system shall be maintained in all pharmacies for humans and non-humans for whom prescriptions, original or refill, are dispensed. The system shall be capable of permitting the retrieval of information. Phar 7.11(3)(b)1.1. Patient’s first and last name, or if not human, name of pet, species and last name of owner. Phar 7.11(3)(b)3.3. Birth date of the patient or, if not human, birth date of the owner. Phar 7.11(3)(b)7.7. Quantity of the drug product or device prescribed, dispensed and remaining. Phar 7.11(3)(c)(c) The pharmacist shall be responsible for attempting to ascertain and record any patient allergies, adverse drug reactions, drug idiosyncrasies, and any chronic conditions which may affect drug therapy as communicated by the patient or agent of the patient. If none, this should be indicated. Phar 7.11(3)(d)(d) Medication profile records shall be maintained for a minimum period of 5 years following the date of the last dispensing. Phar 7.11 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21; correction in (1), (3) (b) 3. made under s. 35.17, Stats., Register December 2020 No. 780. Phar 7.12Phar 7.12 Delegation by a physician. The pharmacist shall document the delegation by a physician under s. 450.033, Stats. The delegated act may not be started prior to the documentation. The documentation shall be maintained for a minimum of 5 years after the last delegated act under that delegation. Phar 7.12 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21; correction made under s. 35.17, Stats., Register December 2020 No. 780. Phar 7.13Phar 7.13 Administration of drug products and devices other than vaccines. Phar 7.13(1)(1) In this section, “course of study” means one or more classes, workshops, seminars, or continuing education programs. Phar 7.13(2)(2) A pharmacist may administer a drug product, as defined in s. 450.01 (11), Stats., or device, as defined in s. 450.01 (6), Stats. After the pharmacist administers a prescribed drug product or device, the pharmacist, a person engaged in the practice of pharmacy under s. 450.03 (1) (f) or (g), Stats., or the pharmacist’s agent shall notify the prescribing practitioner or enter the information in a patient record system shared by the prescribing practitioner. Phar 7.13(3)(3) A pharmacist may not administer by injection a prescribed drug product or device unless the pharmacist has successfully completed a course of study and training in administration technique conducted by a course provider approved by the Accreditation Council for Pharmacy Education or the board. Phar 7.13(4)(4) A person engaged in the practice of pharmacy under s. 450.03 (1) (f) or (g), Stats., may not administer a prescribed drug product or device unless the person satisfies all of the following: Phar 7.13(4)(a)(a) Successfully completes a course of study and training in administration technique conducted by a course provider approved by the Accreditation Council for Pharmacy Education or the board. Phar 7.13(4)(b)(b) Administers the prescribed drug product or device only under the direct supervision of a pharmacist who has successfully completed a course of study and training in administration technique conducted by a course provider approved by the Accreditation Council of Pharmacy Education or the board. Phar 7.13(4)(c)(c) After administering the prescribed drug product or device, notifies the prescribing practitioner or enters the information in a patient record system shared by the prescribing practitioner. Phar 7.13(5)(5) The board may approve courses of study which meet criteria substantially equivalent to criteria used by the Accreditation Council for Pharmacy Education. Phar 7.13(6)(6) A course of study and training in administration technique shall include all of the following topics: Phar 7.13(6)(d)(d) The 5 rights of administration including right patient, right drug, right dose, right route, and right time. Phar 7.13(6)(e)(e) Patient reassessment after administration including signs and symptoms of adverse drug reactions. Phar 7.13(6)(f)(f) Best practices in documentation of the medication administration. Phar 7.13(7)(7) This section does not apply to the administration of vaccines.
/code/admin_code/phar/7
true
administrativecode
/code/admin_code/phar/7/i/10/1/b
Pharmacy Examining Board (Phar)
administrativecode/Phar 7.10(1)(b)
administrativecode/Phar 7.10(1)(b)
section
true
